La cadena de opciones muestra datos clave de las opciones de acciones de Schmid Group a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Schmid Group..

Schmid Group (NASDAQ:SHMD) Bolsa, Cadena de Opciones

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

SCHMID Group N.V. - Class A Ordinary Shares

Schmid Group NV

Shimano Inc

Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) is looking for Q2 Adj EPS of $0.12-$0.32 vs $0.34 analyst estimate. sees sales of $135.000 million-$165.000 million vs $167.60 million analyst estimate.

News

Guidance

VECO

Veeco Instruments Sees Q2 Adj EPS $0.12-$0.32 vs $0.34 Est; Sees Sales $135.000M-$165.000M vs $167.60M Est

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) affirms FY2025 GAAP EPS guidance from $6.15-$6.35 to $6.15-$6.35 vs $6.25 analyst estimate..

Chesapeake Utilities Affirms FY2025 GAAP EPS Guidance of $6.15-$6.35 vs $6.25 Est

Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.81) by 17.28 percent. This is a 61.02 percent decrease over losses of $(0.59) per share from the same period last year.

Earnings

Earnings Misses

SLNO

Soleno Therapeutics Q1 GAAP EPS $(0.95) Misses $(0.81) Estimate

One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) affirms FY2025 sales outlook from $835.00 million-$870.00 million to $835.00 million-$870.00 million vs $844.49 million estimate.

STKS

One Group Hospitality Affirms FY2025 Sales Guidance of $835.00M-$870.00M vs $844.49M Est

One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) sees Q2 sales of $205.000 million-$210.000 million vs $210.06 million analyst estimate.

One Group Hospitality Sees Q2 Sales $205.000M-$210.000M vs $210.06M Est

Buybacks

Montrose Environmental Group Announces Inaugural Stock Repurchase Program Of Up To $40M

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) affirms FY2025 FFO guidance from $0.89-$0.93 to $0.89-$0.93 vs $0.85 analyst estimate..

GMRE

Global Medical REIT Affirms FY2025 AFFO per share Guidance of $0.89-$0.93 vs $0.85 Est

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) reported quarterly earnings of $2.22 per share which missed the analyst consensus estimate of $2.32 by 4.31 percent. This is a 5.71 percent increase over earnings of $2.10 per share from the same period last year. The company reported quarterly sales of $298.70 million which beat the analyst consensus estimate of $252.30 million by 18.39 percent. This is a 21.55 percent increase over sales of $245.74 million the same period last year.

Earnings Beats

Chesapeake Utilities Q1 Adj. EPS $2.22 Misses $2.32 Estimate, Sales $298.70M Beat $252.30M Estimate

Clover Health Investments Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) saw its shares jump more than 12.54% to $3.77 on Wednesday by market close, following better-than-expected profitability in the first quarter, despite missing revenue estimates.
What To Know: The Medicare Advantage-focused insurtech company <a href="https://www.benzinga.com/pressreleases/25/05/g45235056/clover-health-reports-first-quarter-2025-results-and-improves-full-year-2025-guidance">reported</a> quarterly sales of $462.33 million, up 33% year-over-year but below the consensus estimate of $499.56 million.
Membership in its Medicare Advantage plans grew 30% year-over-year to 103,418 members, helping drive improved profitability. Clover reported a GAAP net loss of just $1 million, compared to a $19 million loss a year ago. Adjusted EBITDA <a href="https://www.benzinga.com/pressreleases/25/05/g45235056/clover-health-reports-first-quarter-2025-results-and-improves-full-year-2025-guidance">rose 279% to $26 million</a>, while adjusted net income climbed 322% to $25 million.
The company credited its tech-driven care model, Clover Assistant, for containing medical costs and improving outcomes. For full-year 2025, Clover now expects insurance revenue between $1.8 billion and $1.875 billion and adjusted profitability of up to $70 million. 
Clover shares have now surged 409% over the past year, reflecting renewed investor confidence in the company's approach to Medicare Advantage.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45263291/fed-keeps-rates-steady-warns-of-rising-uncertainty-about-the-economic-outlook">Fed Keeps Rates Steady, Warns Of Rising &#8216;Uncertainty About The Economic Outlook&#8217;</a>
<h2 class="wp-block-heading">How To Buy CLOV Stock</h2>
By now you're likely curious about how to participate in the market for Clover Health Investments, be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Clover Health Investments, which is trading at $3.79 at time of writing, $100 would buy you 26.39 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option or sell a call option at a strike price above where shares are currently trading — either way, it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Clover has a 52-week high of $4.86 and a 52-week low of 79 cents.
Read Next: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45263291/fed-keeps-rates-steady-warns-of-rising-uncertainty-about-the-economic-outlook">• Fed Keeps Rates Steady, Warns Of Rising &#8216;Uncertainty About The Economic Outlook&#8217;</a>
Photo: Shutterstock

Health Care

Movers

CLOV

Clover Health Shares Surge After Strong Q1 Earnings, Now Up 409% Over Past Year

Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>), a leading provider of software and services to communications and media companies, today announced that it has extended a multi-year managed services agreement with M1 Limited (M1), a leading telco and digital services provider in Singapore, to manage M1's new cloud-native online <a href="https://pr.report/a3yb">charging platform</a> delivered earlier this year.
Under the agreement, Amdocs will provide augmented services for this converged (prepaid and postpaid as well as 4G and 5G) charging platform, including operational support and business enhancements. Amdocs will also ensure the system's stability and compliance with Singapore's Critical Information Infrastructure (CII) requirements as well as fulfillment of local regulatory requirements.
"At M1, we are dedicated to achieving operational excellence and providing innovative solutions that drive digital transformation in Singapore and the region," said Marko Cetkovic, Chief Digital Officer at M1. "Our extended collaboration with Amdocs will ensure that our new online charging platform operates at peak performance, enabling us to launch services faster, enhance efficiency and deliver unmatched value to our customers."
"We are proud to strengthen our relationship with M1 as they continue their mission of leveraging cutting-edge technology to evolve the telecommunications landscape in Singapore," said Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs. "As M1 introduces new services to market, Amdocs is committed to supporting their cloud-based scalability, agility and innovation, while improving their quality and efficiency."
Supporting Resources
Learn more about Amdocs <a href="https://pr.report/a3yc">amAIz Suite</a>
Keep up with Amdocs news by visiting the company's <a href="https://pr.report/a3yd">website</a>
Follow us on <a href="https://pr.report/a3ye">X</a>, <a href="https://pr.report/a3yf">Facebook</a>, <a href="https://pr.report/a3yg">LinkedIn</a> and <a href="https://pr.report/a3yh">YouTube</a>
About Amdocs
Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers' innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and enterprise customers. Our employees around the globe are here to accelerate service providers' migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $5.00 billion in fiscal 2024. For more information, visit <a href="https://pr.report/a3yi">www.amdocs.com</a>
Amdocs' Forward-Looking Statement
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2024, filed on December 17, 2024, and our Form 6-K furnished for the first quarter of fiscal 2025 on February 18, 2025.

Contracts

M1 Enters Partnership With Amdocs To Manage Newly Delivered Cloud-Native Charging Platform

Gladstone Commercial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOD#NASDAQ">GOOD</a>) reported quarterly earnings of $0.34 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $37.50 million which beat the analyst consensus estimate of $37.33 million by 0.45 percent. This is a 4.98 percent increase over sales of $35.72 million the same period last year.

GOOD

Gladstone Commercial Q1 Core FFO $0.34, Inline, Sales $37.50M Beat $37.33M Estimate

Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) raises FY2025 GAAP EPS guidance from $11.80-$12.10 to $12.15-$12.50 vs $12.23 analyst estimate. Raises FY2025 sales outlook from $3.33 billion-$3.38 billion to $3.37 billion-$3.42 billion vs $3.36 billion estimate.

Curtiss-Wright Raises FY2025 GAAP EPS Guidance from $11.80-$12.10 to $12.15-$12.50 vs $12.23 Est; Raises FY2025 Sales Guidance from $3.33B-$3.38B to $3.37B-$3.42B vs $3.36B Est

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. This is a 4.35 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $34.59 million which missed the analyst consensus estimate of $35.48 million by 2.49 percent. This is a 1.35 percent decrease over sales of $35.07 million the same period last year.

Global Medical REIT Q1 FFO $0.22 Beats $0.20 Estimate, Rental revenue $34.59M Miss $35.48M Estimate

Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.32 by 15.62 percent. This is a 17.78 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $167.29 million which beat the analyst consensus estimate of $166.24 million by 0.63 percent. This is a 4.12 percent decrease over sales of $174.48 million the same period last year.

Veeco Instruments Q1 Adj. EPS $0.37 Beats $0.32 Estimate, Sales $167.29M Beat $166.24M Estimate

Biotech

General

MYGN

Myriad Genetics Publishes RiskScore Study In JCO Precision Oncology

Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) raises FY2025 Adj EPS guidance from $(0.15)-$(0.09) to $(0.13)-$(0.07) vs $(0.11) analyst estimate. Raises FY2025 sales outlook from $575.00 million-$585.00 million to $585.00 million-$595.00 million vs $578.07 million estimate.

FSLY

Fastly Raises FY2025 Adj EPS Guidance from $(0.15)-$(0.09) to $(0.13)-$(0.07) vs $(0.11) Est; Raises FY2025 Sales Guidance from $575.00M-$585.00M to $585.00M-$595.00M vs $578.07M Est

Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) is looking for Q2 Adj EPS of $(0.08)-$(0.04) vs $(0.04) analyst estimate. sees sales of $143.000 million-$147.000 million vs $140.18 million analyst estimate.

Fastly Sees Q2 Adj EPS $(0.08)-$(0.04) vs $(0.04) Est; Sees Sales $143.000M-$147.000M vs $140.18M Est

Orion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OEC#NYSE">OEC</a>) lowers FY2025 Adj EPS guidance from $1.45-$1.90 to $1.20-$1.70 vs $1.63 analyst estimate..

Orion Lowers FY2025 Adj EPS Guidance from $1.45-$1.90 to $1.20-$1.70 vs $1.63 Est

Atmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>) raises FY2025 GAAP EPS guidance from $7.05-$7.25 to $7.20-$7.30 vs $7.19 analyst estimate..

Atmos Energy Raises FY2025 GAAP EPS Guidance from $7.05-$7.25 to $7.20-$7.30 vs $7.19 Est

Montrose Environmental Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEG#NYSE">MEG</a>) affirms FY2025 sales outlook from $735.00 million-$785.00 million to $735.00 million-$785.00 million vs $754.33 million estimate.

Comments

Schmid Group

Schmid Group (SHMD) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL